Follow
fabrice andre
fabrice andre
Université Paris Sud
Verified email at igr.fr
Title
Cited by
Cited by
Year
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
42752013
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
36032008
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ...
Nature medicine 13 (9), 1050-1059, 2007
33282007
DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy
KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ...
New England Journal of Medicine 355 (10), 983-991, 2006
23222006
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
22162015
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ...
Nature medicine 15 (10), 1170-1178, 2009
20032009
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ...
New England Journal of Medicine 380 (20), 1929-1940, 2019
19632019
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ...
New England journal of medicine 375 (18), 1738-1748, 2016
17792016
Palbociclib in hormone-receptor–positive advanced breast cancer
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
16582015
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ...
New England Journal of Medicine 382 (7), 610-621, 2020
14972020
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
B Escudier, T Dorval, N Chaput, F André, MP Caby, S Novault, C Flament, ...
Journal of translational medicine 3, 1-13, 2005
13182005
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
12242017
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ...
Annals of Oncology 29 (8), 1634-1657, 2018
12182018
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
12132017
Malignant effusions and immunogenic tumour-derived exosomes
F Andre, NEC Schartz, M Movassagh, C Flament, P Pautier, P Morice, ...
The Lancet 360 (9329), 295-305, 2002
11332002
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
10932015
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
10232018
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
10092014
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ...
Annals of Oncology 31 (12), 1623-1649, 2020
9962020
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice …
LN Harris, N Ismaila, LM McShane, DF Hayes
Journal of oncology practice 12 (4), 384-389, 2016
9852016
The system can't perform the operation now. Try again later.
Articles 1–20